- Exploitation strategy
The final goal of our work is to develop a commercial product: new drugs for the treatment of Parkinson’s disease. Within the scope of the IAPP-GDNF mimetics we plan to perform preclinical trials and test efficacy of our small molecules in animal model of human disease. In the case of identification of possible good drug candidate(s) against neurodegenerative diseases (especially against the PD) the valuation of the compounds will be carried out and the further commercialization strategy decided on this basis. In the case of high potential calculated net present value (NPV) for given clinical indication(s) at early preclinical stage, the compounds can be out-licensed to pharmaceutical companies with significant interest in neurotrophic factor mimetics. Commercial partner Molcode Ltd. has strong contact with many of them and has already signed preliminary agreements on this matter.
- IPR strategy
Before publications in open sources discovered molecules will be patented. Initial compounds that we plan to optimize in the current project have already been patented. The ownership rights will be shared by the partners as specified in Consortium Agreement made in accordance with EU regulation.Ownership of inventions will be determined by inventorship. The owner of the invention will grant to the other partner a royalty-free unrestricted licence to use the inventions for academic research and scholarly purposes only.
All project pre-existing materials, inventions, information, technologies and know-hows are exclusive property of the providing side. The other partner is granted a non-transferable non-exclusive licence to use the materials, inventions, information, technologies and know-hows for academic research purposes only as described in the agreement and for the period specified in the agreement.